BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260515T173014
CREATED:20240208T112624Z
LAST-MODIFIED:20240208T112624Z
UID:38638-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:3rd Process Development for Cell Therapies Summit
DESCRIPTION:Driving Process Robustness\, Scalability\, Speed & Affordability \nIn the dynamic cell therapy landscape\, where financial challenges continue to prevail\, the emphasis on innovative process development becomes pivotal. Now\, more than ever\, there’s a heightened demand for cost-effective solutions that bolster scalability and expedite development timelines. \nWelcome to the 3rd Process Development for Cell Therapies Summit\, your paramount gathering dedicated to advancing process robustness\, scalability\, speed\, and affordability. This ensures the rapid advancement of highly efficacious products through clinical trials\, securing a market-ready status with competitive commercial viability. \nWhether you’re on the brink of IND or gearing up for BLA submission\, this gathering of brilliant minds offers an unparalleled opportunity to glean insights form organizations like BMS\, Beam Therapeutics\, 2seventy Bio\, Takeda\, Century Therapeutics\, AstraZeneca\, and more! \nSeize this opportunity to connect with technical experts united in the goal of streamlining process development. Through the sharing of best practices and pre-competitive insights\, let’s collectively drive the streamlined development of consistent\, scalable\, and cost-effective autologous and allogeneic cell therapies. Together\, we can shape the future of cell therapy! \nTo know more visit: https://ter.li/ixkr7z
URL:http://www.pharmajournalist.com/event/3rd-process-development-for-cell-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240612
DTSTAMP:20260515T173014
CREATED:20240502T125908Z
LAST-MODIFIED:20240502T125908Z
UID:39043-1717977600-1718150399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SAE Media Group’s 8th Annual Pre-Filled Syringes West Coast Conference will be back for 2024 in the West Coast to bring together device developers\, biotech and big pharma. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring you key insights to enhance your drug device portfolio\, but it will also give you the opportunity to network with key industry players. We hope to welcome you in June 2024! \nWhat will you gain? \n\nEngage in discussions on evolving EU and US regulations as well as reviewing the latest FDA guidance on human factors and drawing insights from successful notified body opinions for streamlined regulatory compliance.\nGain insight into advancements in large volume drug delivery devices with a case study from Halozyme and a panel discussion assessing key considerations\, benefits and barriers of such devices for stakeholders including patients\, HCPs and pharma companies.\nDelve into comprehensive strategies for maximizing combination product manufacturing and effectively managing your product’s lifecycle with key insights from GSK and Merck\nAcquire insights into human factors best practices from AbbVie and Regeneron\, and discover ways to effectively apply testing and validation approaches for combination products.\nExplore collaborative opportunities to advance innovation in the injectables field and gain insight into the latest technology updates and challenges these pose such as leaching in electro-mechanical devices.
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2024/
LOCATION:SAN DIEGO MARRIOTT LA JOLLA\, 4240 La Jolla Village Drive\, La Jolla\, San Diego\, CA\, 92037\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:EVENTS@SAEMEDIAGROUP.COM
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240613
DTSTAMP:20260515T173014
CREATED:20240215T112047Z
LAST-MODIFIED:20240215T112047Z
UID:38716-1717977600-1718236799@www.pharmajournalist.com
SUMMARY:6th Allogeneic Cell Therapies Summit
DESCRIPTION:The entire cell therapy field is experiencing a shift towards allogeneic platforms as the potential to achieve a truly off-the-shelf\, universal\, and efficacious cell therapy offers great advantages such as reduced cost\, production and patient accessibility compared to its autologous counterparts. \nPlacing a spotlight on what has been deemed the ‘future of cell therapy’\, the 6th Annual Allogeneic Cell Therapies Summit returns to Boston this June as the leading industry focused meeting dedicated to accelerating the safety\, durability and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need. \nAcross a jam-packed agenda consisting of 60+ hours of content\, 3 in-depth tracks\, 1 Investor & Business Development Focus Day\, 1 Beyond Oncology Bootcamp Day and more; our 50+ expert speakers will lead you and your peers in discussions that will help to transform universal cell therapies for patients across the globe. \nLearn more here: https://ter.li/aetc0d
URL:http://www.pharmajournalist.com/event/6th-allogeneic-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240604
DTEND;VALUE=DATE:20240607
DTSTAMP:20260515T173014
CREATED:20240219T105830Z
LAST-MODIFIED:20240219T105830Z
UID:38732-1717459200-1717718399@www.pharmajournalist.com
SUMMARY:Computational RNA Design & Delivery Summit
DESCRIPTION:AI and computational science are revolutionizing the field of RNA therapeutic discovery\, which is empowering biopharma companies to harness the potential of this technology. Join the conversation at the world’s first industry-dedicated Computational RNA Design & Delivery Summit taking place in Boston this June 4 – 6 2024. \nHear what industry pioneers from Sanofi\, Moderna\, Nava Therapeutics\, Nutcracker Therapeutics\, and more have to say\, and deep dive into harnessing AI\, Machine learning\, deep neural networks\, and predictive algorithms for RNA design and delivery to scale and accelerate novel\, cost-effective RNA-based therapeutics. \nHere’s a snapshot of the speaker faculty: \n\nMihir Mektar\, Principal Scientist\, Moderna\nSarah Spencer\, Senior Expert II Data Science\, Novartis\nBenjamin Mead\, Principal Data Scientist\, Nava Therapeutics\nDinghai Zheng\, Machine Learning Senior Scientist\, Sanofi\nEvan McCartney-Melstad\, Director of Bioinformatics\, Nutcracker Therapeutics\nKelly Brock\, Senior Computational Biologist\, Kernal Biologics\n\nThis exclusive meeting has been designed with you in mind! Join 80+ data science\, computational biology/chemistry\, bioinformatic\, and delivery experts to accelerate discovery of your mRNA\, RNAi\, and tRNA modalities and innovate the delivery of these modalities beyond the liver by deep-diving into LNP\, peptide-based\, and AAV delivery chemistry. \nBook your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/computational-rna-design-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240529
DTEND;VALUE=DATE:20240601
DTSTAMP:20260515T173014
CREATED:20240117T112916Z
LAST-MODIFIED:20240119T121741Z
UID:38533-1716940800-1717199999@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Patient Engagement Summit
DESCRIPTION:Patient engagement is a crucial responsibility of any gene therapy company if they’re serious about progressing safe\, effective\, and meaningful therapies to patients. The 4th Gene Therapy Patient Engagement Summit is returning in 2024\, sitting at the unique interface of patient engagement and gene therapy\, from embarking on first in-human trials through to commercial therapeutics. \nDelve into key challenges including engaging in R&D and managing expectations of gene therapies\, language and nomenclature used to educate on what gene therapies are and what it means to participate in a clinical trial\, outlining informed consent to support clinical trial enrollment\, and understanding the latest regulatory requirements to effectively demonstrate that these transformative therapies are meaningful to patients. \nJoin 80+ patient advocacy and engagement professionals from gene therapy companies and patient advocacy groups to gain actionable insights that you can immediately implement into your own gene therapy programs. Unite with the leading voices in this community to develop solutions to the challenges that are unique to the gene therapy space. \nTo learn more and discover the full agenda\, visit the official event website at genetherapy-patient-engagement.com
URL:http://www.pharmajournalist.com/event/4th-gene-therapy-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240522
DTEND;VALUE=DATE:20240525
DTSTAMP:20260515T173014
CREATED:20240103T113206Z
LAST-MODIFIED:20240103T113206Z
UID:38410-1716336000-1716595199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Analytical Development Europe Summit
DESCRIPTION:The 5th Gene Therapy Analytical Development Europe – What to Expect in 2024? \nIn the face of evolving regulatory guidelines and mounting scrutiny\, the 5th Gene Therapy Analytical Development Europe Summit will discuss ways you can apply contemporary analytical tools to guarantee the consistency\, quality\, and safety of your gene therapy products. \nJoin leading CMC\, regulatory\, QC\, analytical and process development experts to gain access to novel data and recent case studies by industry professionals from AstraZeneca\, the MHRA\, Novartis\, Sarepta Therapeutics\, Roche\, Sanofi\, and many more. \nEnjoy in-depth\, valuable networking opportunities with scientists and senior decision makers from small biotech through to large pharma – perfect for those looking to further industry relationships. \nTo know more visit: https://ter.li/vz0jr4
URL:http://www.pharmajournalist.com/event/5th-gene-therapy-analytical-development-europe-summit/
LOCATION:15Hatfields\, Chadwick Court\, London\, SE1 8DJ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240521
DTEND;VALUE=DATE:20240524
DTSTAMP:20260515T173014
CREATED:20240208T111843Z
LAST-MODIFIED:20240208T112145Z
UID:38632-1716249600-1716508799@www.pharmajournalist.com
SUMMARY:6th Annual Treg-Directed Therapies Summit
DESCRIPTION:Driving Next Gen Treg Stimulation for Autoimmunity\, Transplantation & Inflammation \nReturning to Boston for its 6th year\, the 6th Treg-Directed Therapies Summit stands as the singular industry forum shining a spotlight on the groundbreaking research and clinical advancements in CAR-Treg and IL2 mutein therapies. Witness the convergence of leading industry and academic experts as they unite to propel the clinical efficacy of Treg therapies to new heights. \nAs the pioneering and longest-tenured meeting dedicated to optimizing and manipulating Treg-based approaches\, this summit invites you to become part of a community at the forefront of innovation. Gain unparalleled insights into the latest developments driving specificity\, delve into novel cell product design\, and explore the engineering of CAR-Tregs to enhance cell stability and durability. \nDon’t miss this unique opportunity to stay ahead in the dynamic landscape of Treg therapies. Join us and contribute to the ongoing dialogue that shapes the future of cutting-edge medical advancements. \nTo know more visit: https://ter.li/gfpnb0
URL:http://www.pharmajournalist.com/event/6th-annual-treg-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240515
DTEND;VALUE=DATE:20240517
DTSTAMP:20260515T173014
CREATED:20240208T131147Z
LAST-MODIFIED:20240208T131147Z
UID:38664-1715731200-1715903999@www.pharmajournalist.com
SUMMARY:GLP-1-Based Therapeutics Summit
DESCRIPTION:The GLP-1-Based Therapeutics Summit is the Ultimate Industry Forum for Developers of GLP-1-Based Therapeutics Across Different Indications \nThe GLP-1-Based Therapeutics Summit is a once-a-year event\, uniting 60+ industry experts to help advance more specialized\, durable\, and efficacious GLP-1s while investigating commercial opportunities to crystallize pipeline strategy and indication expansion. \nGrab your copy of the full agenda \nAmidst the resounding success of Novo’s SELECT trial\, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments\, propelling GLP-1 players to the forefront of pharmaceutical revenue growth. \nIf you are looking to differentiate your GLP-1 products\, forge new relationships with fellow GLP-1 developers\, or discover the newest innovations in improving the tolerability\, efficacy\, and durability of GLP-1s\, there has never been a more appropriate time to unite and navigate this rapidly evolving space at the GLP-1-Based Therapeutics Summit this May! \nKey Highlights: \nUnraveling Exciting Opportunities to Apply GLP-1 Receptor Agonists Across a Wide Range of Indications\nIncluding cardiovascular\, renal\, obstructive sleep apnea\, MASH\, and neurodegenerative diseases with Eli Lily\, D&D Pharmatech\, and Altimmune \nOptimizing the Efficacy of GLP-1-Based Therapeutics\nHear the newest innovations raising the benchmark for more successful weight loss with Diasome Pharmaceuticals and BioAge Labs \nDeveloping a Robust Commercial Strategy \nDifferentiate your GLP-1 products from your competitors\, to effectively target specific patient segments with Altimmune and Regor Therapeutics
URL:http://www.pharmajournalist.com/event/glp-1-based-therapeutics-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240508
DTEND;VALUE=DATE:20240510
DTSTAMP:20260515T173014
CREATED:20240208T123641Z
LAST-MODIFIED:20240208T123712Z
UID:38645-1715126400-1715299199@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery Conference and Exhibition
DESCRIPTION:The Injectable Drug Delivery Conference returns this year with an unparalleled agenda dedicated to revolutionizing the pharmaceutical and biotechnological landscapes. This pivotal event focuses on cutting-edge advancements in drug-device co-development\, advanced therapeutic modalities\, and the sustainability of injectable drug delivery systems. \n \nWhy Attend? \n\nExplore how devices can be co-developed alongside drug products to foster a collaborative approach\, improving biocompatibility and effective toxicological testing.\nExpand your knowledge on design strategies for injectable delivery of advanced therapies\, including cell and gene therapies\, large molecule delivery\, and navigating the challenges of sub-zero device requirements.\nDive into focused presentations tailored to a technical device development and primary packaging audience\, covering vial material selection\, silicone layer thickness studies\, and the standardization of primary container formats.\nGain comprehensive insights into sustainable device materials\, from development and selection through to disposal.\nLearn from major device developers about streamlining product development and CMC practices for effective compliance post-NDA/MAA approval.\n\nWho Should Attend? \nThis conference is designed for scientists\, R&D professionals\, regulatory specialists\, and anyone at the forefront of drug delivery technology and pharmaceutical device development seeking to network with peers\, learn from industry leaders\, and stay ahead of the curve in injectable drug delivery innovations. \nAdditional Information: \nAttendees can expect to leave with actionable insights and strategies to apply within their own practices and organisations. This conference offers a unique opportunity to connect with like-minded professionals and pioneers in the field. \nRegister now to secure your spot at the forefront of injectable drug delivery innovation!
URL:http://www.pharmajournalist.com/event/injectable-drug-delivery-conference-and-exhibition/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240507
DTEND;VALUE=DATE:20240510
DTSTAMP:20260515T173014
CREATED:20240117T105624Z
LAST-MODIFIED:20240117T120808Z
UID:38511-1715040000-1715299199@www.pharmajournalist.com
SUMMARY:3rd Next Generation RNA Therapeutics Summit
DESCRIPTION:The field of next generation RNA therapeutics continues to progress towards clinical translation\, poised with investments and collaborations. Yet\, key challenges like sequence design\, purity\, stability\, safety and translatability into clinical settings continue to prevent their full therapeutic potential from being realized. \nReuniting everyone involved in next generation RNA therapeutic development\, from Scientists and Academics to C-Level Executives\, the 3rd Next Generation RNA Therapeutics Summit returns to cover the depth and breadth of next generation RNAs\, including circular RNA\, self-amplifying RNA\, and more. \nWhere: Hilton Boston Bay Back\, Boston\, Massachusetts \nWhen: May 7-9\, 2024 \nWebsite: https://ter.li/7sk7zz \n\n20+ brand new case studies from leading biopharma\, including Pfizer\, Strand Therapeutics\, and Laronde\nInvestment and collaboration fireside chat\n3 interactive workshops on targeted delivery\, purification challenges\, and enabling next generation RNA therapeutic production\nYour opportunity to share your work in the Scientific Poster Session\n\nWhat’s next:  \nDownload your copy of the brochure: https://ter.li/7sk7zz \nRegister your place: https://ter.li/5jyjfj
URL:http://www.pharmajournalist.com/event/3rd-next-generation-rna-therapeutics-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240429
DTEND;VALUE=DATE:20240503
DTSTAMP:20260515T173014
CREATED:20231124T115148Z
LAST-MODIFIED:20231124T115309Z
UID:38225-1714348800-1714694399@www.pharmajournalist.com
SUMMARY:3rd LNP Formulation & Process Development Summit
DESCRIPTION:Following the success of the first 2 years of the LNP Formulation & Process Development Summit\, we are hugely excited to announce the much-anticipated return of this world-leading summit in 2024. \nThis April\, the 3rd LNP Formulation & Process Development Summit returns to Boston\, bringing together over 400 experts in LNP Biology\, Chemistry\, Formulation\, Analytical Development\, Process Development\, Manufacturing and more. This is your ultimate platform for sharing insights\, learning new concepts and networking to propel more LNPs into the clinic in 2024. \nJoin the ever-growing community of LNP pioneers as they tackle the challenges associated with developing safe\, compliant and efficacious LNPs\, to treat a variety of disease indications at a variety of target organs. This starts with the in vitro discovery of LNPs through to the manufacturing processes\, with end-to-end synergy fundamental. \nHear from industry powerhouses Pfizer\, Moderna\, Alnylam and more\, as well as new companies to share their insights to this community including Capstan Therapeutics\, AbbVie\, Mana Bio\, Serina Therapeutics\, Karma Biotechnologies and more. \nWith an expanded content offering and a 4-track\, 4-day summit format\, we continue to be the most comprehensive\, premium LNP content available to industry. Part of this year’s content growth\, the addition of the ‘LNP IP & Commercial Partnerships Focus Day’ has evolved with the current industry trends to secure long standing partnership to demonstrate clinical results\, as well as gaining a further handle on the current IP and legal landscape. \nTo know more visit: https://ter.li/s96la3
URL:http://www.pharmajournalist.com/event/3rd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T173014
CREATED:20240213T103635Z
LAST-MODIFIED:20240213T103635Z
UID:38695-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Peptide Based Therapeutics Summit
DESCRIPTION:Positioned in the goldilocks spot between small molecules and biologics\, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies\, together with novel design and delivery strategies to surmount their inherent drawbacks\, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck\, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs. \nThe first industry-focused event dedicated towards this exciting new modality\, the Peptide Based Therapeutics Summit will unite pioneers from Johnson & Johnson\, Fog Pharma\, Genentech & PeptiDream\, spanning diverse diseases and therapeutic approaches. Whether you’re focused on peptide-drug conjugates\, bicyclic or macro-cyclic peptides\, PCSK9\, GLP\, or any other peptide based therapeutic\, this is an invaluable opportunity to learn from peers\, accelerate discovery and de-risk the development of your peptide therapeutics. \nAs we enter the third wave of peptide-based therapeutics\, this therapeutic and disease agnostic meeting will bring together the leading minds in early discovery\, pre-formulation\, heads of peptide drug development and pioneering peptide chemists. Together\, we will dissect challenges related to improving peptide stability\, raising oral bioavailability and balancing cell permeability with intracellular target selectivity\, as well as exploring how the latest cutting-edge technology can help you arrive at the optimal lead compound. \nLearn more about this meeting that helps to shape the trajectory of these remarkable drugs across various therapeutic landscapes: https://ter.li/2qs54c
URL:http://www.pharmajournalist.com/event/peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T173014
CREATED:20240123T114632Z
LAST-MODIFIED:20240126T122455Z
UID:38558-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Exosome Characterization & Analytical Development Summit
DESCRIPTION:In the ever-evolving exosome field\, the past year has witnessed remarkable progress. From Kimera’s FDA IND approval to Brexogen’s recent deal with HK inno.N and advancements in analytical technology\, the landscape is rapidly advancing. Developing robust techniques is increasingly crucial\, serving as the cornerstone for exosome therapeutics\, alongside drug delivery applications and advancements. \n \nThe Exosome Characterization & Analytical Development Summit offers a comprehensive forum\, equipping you with the skills needed to establish robust techniques\, select the best instruments\, ensure quality\, and seamlessly navigate regulatory processes. \nAcross three days in April\, this hotly anticipated summit will unite key experts from AbbVie\, Aegle Therapeutics\, Vesigen Therapeutics\, and more to unite an industry on: \n\nIn depth technical content of exosome analysis and parameters for confidence in quality\nDefining standardized tools and techniques while keeping regulatory guidance in mind for clinical progression\nBridging communications and networking between Analytical Experts and Decision Makers\n\nTo learn more\, and secure your place\, check out the official event website here: https://ter.li/v1xubp \nDownload the full event guide here: https://ter.li/182ula
URL:http://www.pharmajournalist.com/event/exosome-characterization-analytical-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T173014
CREATED:20240117T110146Z
LAST-MODIFIED:20240131T105720Z
UID:38516-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:As European biopharma seek regulatory clarity to progress their mRNA process development and manufacturing\, the 2nd mRNA Process Development & Manufacturing Summit Europe returns to help you improve and optimise purification processes\, platforms for circular and saRNAs and drug product formulation. \nWhere: Crowne Plaza Frankfurt – Congress Hotel\, Frankfurt\, Germany \nWhen: 23-25th April\, 2024 \nWebsite: https://ter.li/d3ggdb \n \nReuniting directors\, heads and senior scientists pioneering the European mRNA space\, this three-day industry forum will navigate key bottlenecks from mRNA sequence design to in vitro transcription and scaling up processes. \n\nGain clarity on regulatory quality standards and comparability changes with the MHRA and CureVac\nExplore continuous platform technologies to accelerate low cost manufacturing\nGlean insights into purification and computational modelling approaches to optimise downstream processes\nHarness platform technologies for circular and self-amplifying RNAs to enhance their manufacturability\nImprove your drug product formulation and manufacturing for personalised mRNA-based medicines\n\nWhat’s next:  \n\nDownload your copy of the brochure: https://ter.li/d3ggdb\nRegister your place: https://ter.li/lzwg6z
URL:http://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Crowne Plaza Frankfurt – Congress Hotel\, Lyoner Str. 44 -48\, Frankfurt am Main\, 60528\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T173014
CREATED:20240103T125432Z
LAST-MODIFIED:20240103T131021Z
UID:38428-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:5th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The 5th TCR-based Therapies for Solid Tumors Summit returns is back as the exclusive gathering where TCR pipelines take center stage. It serves as the premier platform for networking with biopharma industry leaders dedicated to expediting the clinical and commercial development of TCR-based therapeutics. \nThis summit serves as the epicenter for exploring these transformative advancements\, poised to showcase the long-term efficacy of TCR therapies in the treatment of solid tumors\, marking a monumental milestone in the field’s evolution. \nThis is your opportunity to accelerate next generation TCR engineering\, enhance target identification\, & improve solid tumor persistence to transform clinical & scalable development for patients in need. Join TScan Therapeutics\, Marengo Therapeutics\, T-Cypher Bio and more to gain invaluable insights into the future of TCR-based therapies. \nFind out more here: https://ter.li/f8jhfw
URL:http://www.pharmajournalist.com/event/5th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240422
DTEND;VALUE=DATE:20240425
DTSTAMP:20260515T173014
CREATED:20240125T115520Z
LAST-MODIFIED:20240125T115520Z
UID:38573-1713744000-1714003199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices East Coast Conference and Exhibition
DESCRIPTION:SAE Media Group’s 11th Annual Pre-Filled Syringes East Coast Conference will return to Boston in April 2024 to bring you the latest advances in the combination product drug delivery space. The 2024 conference will be bigger and better than ever\, bringing you 3 days of expertise\, comprising of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference with morning keynote plenaries and parallel afternoon topic streams addressing the industry’s hottest topics through case studies and industry insights. \nThis event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in April 2024! \nWhy attend: \n\n3 full days of networking opportunities\n40+ presentations with 75% of speakers from the top 20 big pharma companies\nThe agenda has been curated by an advisory board of big pharma and biotech opinion leaders providing expertise focused on device development\, regulatory affairs and quality\nAccess a focus day and 4 dedicated streams addressing the hottest topics in the industry\n\nThis year’s agenda has been validated by our 2024 advisory board: \nJohn Schalago\, Executive Director\, Senior Global Program Director\, Novartis\nKhaudeja Bano\, Vice President\, Combination Product Quality\, Amgen\nJames P. Wabby\, Global Head\, Regulatory Affairs – Emerging Device Technologies and Combination Products\, AbbVie\nMark DeStefano\, Director\, Combination Products and Devices R&D\, Teva\nMichael Song\, Director\, Drug Product Development\, Moderna \nWhat you will gain: \n\nCollaborate with pharma\, biotech and device developers across 3 full days on the latest trends\, advancements and challenges within the pre-filled syringe and injectable device market\nHear about new technological advances for challenging to delivery drugs such as large volume\, highly viscous and lyophilised formulations with case studies on wearable injectors and more\nUnderstand the latest regulatory requirements from experts surrounding combination products and engage in opportunities for collaboration and needs for advancing innovation in the field with an advisory board fireside chat\nGain insight into how big pharma is incorporating sustainable approaches into drug device design and lifecycle management\nDelve into the growing potential of digital health to improve patient experience and treatment\, and the challenges facing its implementation\nExamine how container and packaging development can support the ever-evolving innovations drug development\, including case studies on CCIT in deep-cold storage and formulator perspectives\n\nTo know more visit: www.pfsamericas.com/PharmaJournalist-Event-Listing
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-east-coast-conference-and-exhibition/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T173014
CREATED:20240213T101859Z
LAST-MODIFIED:20240213T101859Z
UID:38680-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Muscular Disorders
DESCRIPTION:Discover the forefront of gene therapy at the 4th Gene Therapy for Muscular Disorders Summit (April 16-18\, Boston). Following the groundbreaking approval of Sarepta’s DMD gene therapy in June 2023\, our April 2024 gathering explores key challenges in translating research into clinical breakthroughs. With a sharp focus on safety and efficacy\, we unite experts to advance transformative treatments for muscular disorders lacking viable options. Join us to propel innovation forward and make a tangible impact on patient care. This is your opportunity to shape the future of muscular disorder treatments in just one event. \nWant to learn more? Check out the event guide here: https://ter.li/cjxppp
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-muscular-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T173014
CREATED:20240111T102149Z
LAST-MODIFIED:20240326T141147Z
UID:38478-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Fc-Mediated Function Summit
DESCRIPTION:Discover & Shape the Future of Biologics & Antibody Therapies at the 4th Fc-Mediated Function Summit \nFINAL 5 PASSES REMAINING – Register Now at https://ter.li/g5st7q \nAt the intersection of groundbreaking research\, clinical innovation\, and collaborative networking\, the 4th Fc-Mediated Function Summit stands as a beacon for advancing the frontier of FcRn\, FcγR\, and IgG therapeutics. Our mission is to supercharge molecular development\, elevate clinical utility\, and explore novel therapeutic applications through a comprehensive understanding of targets and biology. \nIn a landscape where clinical data is expanding\, and partnerships like the Argenx-Genmab powerhouse exemplifying the potential of antibody therapies\, the spotlight on biologics Fc modulation as a therapeutic target has been more intense than ever. The 4th Fc-Mediated Function Summit continues to be at the forefront of this movement\, uniting experts and enthusiasts alike. \nKey Highlights: \nTargeting FcRn & FcγR Biology: \nUnlock the secrets of molecular engineering and real-world clinical outcomes by focusing on the critical targets – FcRn and FcγR. Gain insights into the intricacies of their biological pathways\, and understand how molecular modifications can translate into tangible clinical benefits. \nUnrivaled Content: \nAs the only conference dedicated exclusively to FcRn\, this meeting will comprehensively cover the landscape. Attendees can expect to be immersed in cutting-edge research\, the latest advancements\, and a holistic understanding of the subject matter. This focus ensures that participants are at the forefront of knowledge and equipped with insights that are not diluted by unrelated topics\, setting this summit apart as a beacon of specialized expertise. \nExceptional Networking: \nForge meaningful connections with a diverse cohort of professionals spanning immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology. The summit provides a unique opportunity to engage with 80+ peers\, facilitating cross-disciplinary partnerships and knowledge exchange.
URL:http://www.pharmajournalist.com/event/4th-fc-mediated-function-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T173014
CREATED:20231215T122902Z
LAST-MODIFIED:20231215T123125Z
UID:38368-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:3rd ADC Analytical Development Summit
DESCRIPTION:The 3rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure you are developing a high-quality ADC product within regulatory boundaries. \nNext year’s program promises to give you even more focused content to better quantify DAR and drug distribution\, overcome species separation challenges\, and better utilize impurity assays to measure free-linker drug and process-related impurities. \nGet an exclusive sneak peek of the agenda here. \nNot only is this meeting packed with technical content that will allow you to influence\, gain a deeper understanding\, and improve product quality\, but it will also give you the opportunity to interact with industry experts including: \n\nNailing Zhang\, Lead Biologist\, FDA\nLinda Nelson\, Executive Director\, RA-CMC\, Daiichi Sankyo\nDavid Lee\, Executive Director\, Analytical Chemistry\, Mersana Therapeutics\nChris Woods\, Scientist\, Analytical Development\, Seagen\nMadhumati Mukherjee\, Senior Scientist\, AstraZeneca\nDengyun (Daisy) Sun\, Principal Scientist\, Cell Based Sciences\, Merck & Co.\nYan-Hui Liu\, Director\, Analytical Development\, GlaxoSmithKline\n\n…and many more! \nSee the full speaker lineup and agenda sessions here. \nWe hope you can join us to network with like-minded colleagues and scientists and have the in-depth technical conversations needed to address the common analytical bottlenecks in ADC development.
URL:http://www.pharmajournalist.com/event/3rd-adc-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240409
DTEND;VALUE=DATE:20240412
DTSTAMP:20260515T173014
CREATED:20240116T093630Z
LAST-MODIFIED:20240116T093700Z
UID:38503-1712620800-1712879999@www.pharmajournalist.com
SUMMARY:Measuring Patient Engagement Summit
DESCRIPTION:The Measuring Patient Engagement Summit is the definitive conference for practical answers. This event will act as the honeypot gathering for leading patient engagement experts to share their latest experiences of how they are successfully measuring patient engagement to: inform decision making in improving patient engagement\, quantify the impact of patient engagement on recruitment and retention\, and ensure the most meaningful outreach to patients and advocacy groups. \n \nJoin 70+ Chief Patient Officers\, Patient Engagement leaders and Patient Advocacy experts\, from esteemed pharmaceutical and biotech companies\, such as Novartis\, Otsuka\, Boehringer Ingelheim\, AstraZeneca and many more\, to establish a roadmap to quantify the success of your patient engagement work. \n  \nCheck out the full event guide now: https://ter.li/cqba4m
URL:http://www.pharmajournalist.com/event/measuring-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240330
DTSTAMP:20260515T173014
CREATED:20240103T114154Z
LAST-MODIFIED:20240103T114154Z
UID:38420-1711411200-1711756799@www.pharmajournalist.com
SUMMARY:7th Gene Therapy for Rare Disorders Summit
DESCRIPTION:This past year has seen more gene therapies approved by the FDA than the previous five years combined\, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. \nTo maximize the value of your late-stage gene therapy assets\, the 7th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical\, manufacturing\, regulatory\, and commercial challenges facing gene therapy programs today. \nBringing together key figures from industry\, regulatory bodies\, patient non-profits\, payers\, and key service providers\, this is the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic. \nJoin us to leverage essential insights from over 300 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market. Keep your finger on the pulse\, form connections with top decision-makers\, and address your specific clinical\, manufacturing\, regulatory\, and commercial bottlenecks to safeguard against costly delays and progress your gene therapies through the pipeline quickly and safely. \nTo know more visit: https://ter.li/x4qqur
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-for-rare-disorders-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T173014
CREATED:20231201T114649Z
LAST-MODIFIED:20231201T143620Z
UID:38253-1711411200-1711583999@www.pharmajournalist.com
SUMMARY:Pharma USA 2024
DESCRIPTION:Accelerate patient value. Pioneer healthcare’s transformation.  \nHealthcare reforms are finally paving the way to affordable access to medicines\, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients. \nThe key? Delivering aligned value to HCPs\, patients\, payers and regulators. \nSpeed and scale is non-negotiable. Those afraid to accelerate will be left behind. We must adapt to evolving payer needs\, empower HCPs with crucial insights\, bridge regulatory gaps and co-create with patients. Only then will we achieve exceptional outcomes. \nReuters Events: Pharma USA 2024 is where senior pharma executives from Commercial\, Marketing\, Medical Affairs\, RWE\, Market Access\, Patient Engagement\, as well as key stakeholders\, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation. \nJoin over 1\,200 of North America’s pharma pioneers\, leading solutions provider\, and patient advocates to sharpen short-term strategy and unite for a long-term future to exceed stakeholder desires across the value chain. \nTo know more visit: https://bit.ly/3GpdsrU
URL:http://www.pharmajournalist.com/event/pharma-usa-2024/
LOCATION:Pennsylvania Convention Center\, 1101 Arch Street\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Kana.Hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240329
DTSTAMP:20260515T173014
CREATED:20231107T111306Z
LAST-MODIFIED:20231107T111306Z
UID:38097-1711411200-1711670399@www.pharmajournalist.com
SUMMARY:5th Glioblastoma Drug Development Summit
DESCRIPTION:The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech\, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. \nDiscover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential\, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success. \nWith promising clinical readouts from a range of therapeutic modalities\, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy\, there is more potential than ever before to be unlocked within the GBM space. \nTo elevate your current standards\, join this unique collaboration between industry giants such as Novartis\, pioneering biotechs such as Day One Biopharmaceuticals\, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives. \nAccess the complete agenda here including a packed pre-workshop conference day\, panel discussions\, poster sessions and important networking opportunities.
URL:http://www.pharmajournalist.com/event/5th-glioblastoma-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T173014
CREATED:20231120T150249Z
LAST-MODIFIED:20231120T150249Z
UID:38186-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:5th Supply Chain & Logistics for Cell Therapies Summit
DESCRIPTION:As the cell therapy field rapidly expands\, keeping ahead of the race by creating a visible and robust supply chain has never been more critical to ensure you have the skills and strategy to develop into the next stage of your pipeline. \nJoin us at the 5th Supply Chain & Logistics for Cell Therapies Summit in Boston from March 25-27th. This summit will bring together logistics and clinical operations experts to establish standardized best practices in planning\, communication and assist companies in scaling up to consistently deliver cell therapies safely\, on time\, and in a cost-effective process. \nSeize the opportunity to enhance your expertise in cell therapy logistics by connecting with leaders in clinical operations\, including esteemed companies like Beam Therapeutics\, Lovance\, Arcellx\, Jassen Pharmaceuticals\, and more. \nDownload the event guide to learn more: https://ter.li/d6jto3
URL:http://www.pharmajournalist.com/event/5th-supply-chain-logistics-for-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T173014
CREATED:20231115T103534Z
LAST-MODIFIED:20231115T103534Z
UID:38132-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:6th Neuroimmunology Drug Development Summit
DESCRIPTION:Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development\, the 6th Neuroimmunology Drug Development Summit is the industry-choice\, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials. \nWhat are the top features to look forward to in 2024? \n\nDoubled pre-conference workshop content\, with 6 deep-dive sessions tailored to your discovery biology and translational expertise led by neuroimmunology leaders from Lundbeck\, Sanofi\, Merck\, Regeneron\, and more\nAgenda content spotlighted neurodegeneration – including TREM2 clinical data updates and breaking down trial design and rationale with Alector and Vigil Neuroscience\nNew case studies beyond microglia\, with sessions spearheading astrocyte function and therapeutic intervention from Sanofi\, IMNEWRUN\, and UCL\nBrand-new content on immunocompetent brain organoids to recapitulate and investigate complex neuroimmune interactions with Roche and Herophilus\nIt is the biggest and most comprehensive program to date\, with 38+ industry and academic speakers\, including new presenting companies Eisai\, EMD Serono\, Ventus Therapeutics\, PTC Therapeutics\, and Inflammasome Therapeutics\n\nUniting 100+ all-star leaders across industry and academia\, this is the must-attend forum for anyone working on treatments targeting neuroinflammation across neurological indications and looking to accelerate their candidates into the clinic in 2024. \nTo know more visit: https://ter.li/wb3bhh
URL:http://www.pharmajournalist.com/event/6th-neuroimmunology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T173014
CREATED:20231207T115623Z
LAST-MODIFIED:20231207T115623Z
UID:38307-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:2nd Targeted Intracellular Delivery Summit
DESCRIPTION:Step into the 2nd Targeted Intracellular Delivery Summit\, a thrilling exploration of cutting-edge advancements in drug delivery. This year\, we redefine possibilities\, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms. \nOptimize drug delivery\, overcome endosomal challenges\, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop Day. Gain insights into targeted cell interventions for cancer and autoimmune diseases\, re-thinking innovative delivery platforms and strategies for cargo delivery into novel targets. \nEngage in transformative discussions and exclusive case studies with industry giants like Sanofi\, Merck & Co\, Sana Biotechnology\, and Capstan Therapeutics. Uniting C-Level Executives\, Researchers\, and Directors\, this event is the only industry-led forum focused on cellular mechanisms to enable targeted intracellular drug delivery. Addressing challenges in compartmentalization and endosomal escape\, it aims to optimize therapeutic efficacy and minimize toxicity. \nJoin us in March 2024 to delve into the forefront of intracellular targeting\, where innovation meets expertise to propel your drug pipelines toward unprecedented success. \nTo know more visit: https://ter.li/p72w9g
URL:http://www.pharmajournalist.com/event/2nd-targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T173014
CREATED:20231207T114720Z
LAST-MODIFIED:20231207T114720Z
UID:38297-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Wet AMD & Diabetic Eye Disease Drug Development Summit
DESCRIPTION:The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer\, Boehringer Ingelheim\, Genentech\, Novartis and OcuTerra\, at the only industry-dedicated forum to transform the potential of treatment of chronic\, sight-threatening retinal vascular diseases to improve patient outcomes. \n \nNew additions for 2024 include: \n\nFresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics\, Bayer\, Boehringer Ingelheim\, OcuTerra\, Novartis\, Genentech\, and Adverum Biotechnologies\n16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models\, choroidal neovascularization\, retinal inflammation\, durable drug delivery to the retinal vascular system and more\nRobust new content focusing on industry-specific topics such as new targets\, in vivo and in vitro models\, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization\n\nTo know more visit: https://ter.li/cjnu7k
URL:http://www.pharmajournalist.com/event/4th-wet-amd-diabetic-eye-disease-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T173014
CREATED:20231207T113944Z
LAST-MODIFIED:20231207T113944Z
UID:38292-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Operationalize Expanded Access Programs Summit
DESCRIPTION:Following the increasing interest in access to investigational medicines from patients\, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. \nBack in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support. \nReunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system\, define a clear exit strategy\, understand updated local and global regulations\, and determine the role of real-world data to optimize the operationalization of your EAP. This is your one-stop shop to capturing industry’s latest case studies in setting up a program globally\, reaching physicians and patients\, collecting real-world data\, and maximizing vendor selection to improve the operationalization of EAP and streamline access to life-changing therapies. \nWhat’s New for 2024? \n\nA deep dive into the country-level challenges and regulators’ requirements along with the best practices for labelling\, shipping\, and reporting to deliver a successful project across the US\, LATAM and Middle East with UCB\, GSK\, Novartis\, Biogen\, Sanofi\, SpringWorks Therapeutics and Day One Biopharmaceuticals\nA delve into the experiences and perspectives of physicians to better understand their pain points and how they become aware of EAPs to strengthen these relationships and move the field forward with the University of Michigan and Riboscience\nAn active discussion into the role of real-world data and the setup of an EAP through value-based organisations to obtain a large community of patients and carry this out with ease with AstraZeneca\n\nDon’t miss out on your opportunity to be amongst physicians\, patients and passionate EAP and clinical supply experts from Novartis\, Daiichi Sankyo\, GSK\, AstraZeneca\, Gilead\, Biogen\, Sanofi\, Eli Lilly\, Regeneron\, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently. \nTo know more visit: https://operationalize-eap.com/
URL:http://www.pharmajournalist.com/event/4th-operationalize-expanded-access-programs-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T173014
CREATED:20231116T104232Z
LAST-MODIFIED:20231116T104232Z
UID:38153-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Potency Assay Summit
DESCRIPTION:In the dynamic cell therapy landscape\, the challenge of potency assay development looms large\, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years. \nAt the 3rd Cell Therapy Potency Assay Summit\, we bring together over 120 analytical\, quality control\, and regulatory experts including esteemed organizations like BMS\, J&J\, Atara Biotherapeutics\, Fate Therapeutics\, Health Canada. The summit will address these pressing concerns with the goal to collaboratively design more effective potency assays that not only streamline regulatory approval but also reduce hold times significantly. \nJoin us and leave equipped with industry insights that enable you to develop practical and reproducible assays\, providing a deeper understanding of your cell therapy products. \nFind out more here: https://ter.li/e448ls
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-potency-assay-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T173014
CREATED:20231108T095535Z
LAST-MODIFIED:20231109T143458Z
UID:38106-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:6th CKD Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for CKD Drug Development \nAdvance More Personalized Therapies for Rare & Common Kidney Diseases \nThe 6th CKD Drug Development Summit is the definitive forum for KOLs\, industry experts\, and regulators to bring kidney innovation onto the next generation of drug development\, uniting 200+ biopharma stakeholders\, from scientific research to clinical development and outcomes\, across three days of concentrated discussion. \nFrom uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology\, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm\, join Novo Nordisk\, Boehringer Ingelheim\, Eli Lilly\, AstraZeneca\, the FDA\, Regeneron\, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.
URL:http://www.pharmajournalist.com/event/6th-ckd-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR